trial
as of 2026-07-01The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NCTId NCT03166098
at a glance
Phase — · Completed
Enrollment 139 (actual)
Sponsored by NYU Langone Health
Primary completion 2022-03-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
139 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2016-07-05
Primary completion
2022-03-01
Eligibility
ALL · 18 Years · 30 Years
Interventions & indications
Sponsors
NYU Langone HealthLead Sponsor
Investigators
1
Mariana Lazar, MDPrincipal Investigator
Sites
1 total
New York, United States
Facts & assertions
4 sourced
Enrollment
139
Phase
NA
Primary Completion Date
2022-03-01
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
investigator
person